首页> 美国卫生研究院文献>Scientific Reports >Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review
【2h】

Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review

机译:食管癌调强放疗后的放射性肺炎:机构数据和系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Radiation pneumonitis (RP) is a serious complication that can occur after thoracic radiotherapy. The goal of this study is to investigate the incidence of RP after radiochemotherapy with intensity modulated radiotherapy (IMRT) in patients with esophageal cancer and correlate this with dose volume histogram (DVH) related parameters. For this purpose, the clinical course of 73 patients was evaluated and irradiation doses to the lungs were extracted from radiotherapy treatment plans. Furthermore, a systematic review on this topic was conducted across PubMed. In our institutional cohort, Common Terminology Criteria for Adverse Events (CTCAE) grade II or higher RP occurred in four patients (5.5%). The systematic review identified 493 titles of which 19 studies reporting 874 patients qualified for the final analysis. No grade IV or V RP after radiochemotherapy with IMRT for esophageal cancer was reported in the screened literature. Grade II or higher RP is reported in 6.6% of the patients. A higher incidence can be seen with increasing values for lung V20. In conclusion, our institutional data and the literature consistently show a low incidence of symptomatic RP after radiochemotherapy in patients with esophageal cancer treated with IMRT. However, efforts should be made to keep the lung V20 below 23% and specific caution is warranted in patients with pre-existing lung conditions.
机译:放射性肺炎(RP)是一种严重的并发症,可在胸腔放疗后发生。这项研究的目的是调查食管癌患者放疗后加调强放疗(IMRT)后RP的发生率,并将其与剂量直方图(DVH)相关参数相关联。为此,对73名患者的临床病程进行了评估,并从放射治疗计划中提取了对肺的照射剂量。此外,在PubMed上对该主题进行了系统的审查。在我们的机构队列中,有4名患者(5.5%)发生了II级或更高RP的不良事件通用术语标准(CTCAE)。系统评价确定了493个标题,其中19个研究报告了874名患者符合最终分析的条件。经筛选的文献中,没有报道IMRT放疗后食管癌的IV级或V RP级。据报道,有6.6%的患者达到II级或更高的RP。随着肺V20值的增加,可以看到更高的发病率。总之,我们的机构数据和文献一致显示,在接受IMRT治疗的食管癌患者中,放化疗后症状性RP的发生率较低。但是,应努力将肺V20保持在23%以下,对于已存在肺部疾病的患者应特别注意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号